Lv4
450 积分 2022-05-05 加入
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
3天前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
17天前
已完结
Associations of adipose tissue insulin resistance with fasting blood glucose and HbA1c in adults without diabetes
24天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
28天前
已完结
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis
29天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
1个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
1个月前
已完结
Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants
2个月前
已完结
Redefining heart failure subtypes according to skeletal muscle mass
2个月前
已完结
皖公网安备34019202002308
